Yoon Sang Min, Kim Dae Yong, Kim Tae Hyun, Jung Kyung Hae, Chang Hee Jin, Koom Woong Sub, Lim Seok-Byung, Choi Hyo Seong, Jeong Seung-Yong, Park Jae-Gahb
Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea.
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1167-72. doi: 10.1016/j.ijrobp.2007.04.047.
To identify pretreatment clinical parameters that could predict pathologic tumor response to preoperative chemoradiotherapy (CRT) for rectal cancer.
The study involved 351 patients who underwent preoperative CRT followed by surgery between October 2001 and July 2006. Tumor responses to preoperative CRT were assessed in terms of tumor downstaging and tumor regression. Statistical analyses were performed to identify clinical factors associated with pathologic tumor response.
Tumor downstaging (defined as ypT2 or less) was observed in 167 patients (47.6%), whereas tumor regression (defined as Dworak's Regression Grades 3 or 4) was observed in 103 patients (29.3%) and complete regression in 51 patients (14.5%). Multivariate analysis found that predictors of downstaging were pretreatment hemoglobin level (p = 0.045), cN0 classification (p < 0.001), and serum carcinoembryonic antigen (CEA) level (p < 0.001), that predictors of tumor regression were cN0 classification (p = 0.044) and CEA level (p < 0.001), and that the predictor of complete regression was CEA level (p = 0.004).
The data suggest that pretreatment CEA level is the most important clinical predictor of pathologic tumor response. It may be of benefit in the selection of treatment options as well as the assessment of individual prognosis.
确定能够预测直肠癌术前放化疗(CRT)后病理肿瘤反应的预处理临床参数。
该研究纳入了2001年10月至2006年7月期间接受术前CRT并随后接受手术的351例患者。根据肿瘤降期和肿瘤退缩评估术前CRT的肿瘤反应。进行统计分析以确定与病理肿瘤反应相关的临床因素。
167例患者(47.6%)出现肿瘤降期(定义为ypT2或更低),而103例患者(29.3%)出现肿瘤退缩(定义为德沃拉克退缩分级3或4),51例患者(14.5%)出现完全退缩。多因素分析发现,降期的预测因素为预处理血红蛋白水平(p = 0.045)、cN0分类(p < 0.001)和血清癌胚抗原(CEA)水平(p < 0.001);肿瘤退缩的预测因素为cN0分类(p = 0.044)和CEA水平(p < 0.001);完全退缩的预测因素为CEA水平(p = 0.004)。
数据表明,预处理CEA水平是病理肿瘤反应最重要的临床预测指标。它可能有助于治疗方案的选择以及个体预后的评估。